Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
Frontiers in Immunology|March 14, 2019
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor ControlNatalia K Botelho, Benjamin O Tschumi, Jeffrey A Hubbell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugatesValérie Cesson, Kathrin Stirnemann, Bruno Robert, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cellsClaire Germain, Christel Larbouret, Valérie Cesson, et al.Frontiers in Oncology|September 21, 2018
Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor GrowthPaola Lasso, Alejandra Gomez-Cadena, Claudia Urueña, et al.Frontiers in Immunology|December 14, 2020
An Immunomodulatory Gallotanin-Rich Fraction From <i>Caesalpinia spinosa</i> Enhances the Therapeutic Effect of Anti-PD-L1 in MelanomaPaola Lasso, Alejandra Gomez-Cadena, Claudia Urueña, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2014
Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector functionLianjun Zhang, Benjamin O Tschumi, Stéphanie Corgnac, et al.Cancer Research|October 17, 2008
Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cellsPrisca Schuler, Emmanuel Contassot, Magali Irla, et al.Frontiers in Immunology|December 27, 2016
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma PatientsTimothy Murray, Silvia A Fuertes Marraco, Petra Baumgaertner, et al.Cancer Immunology, Immunotherapy : CII|December 18, 2012
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responsesStéphanie Corgnac, Rachel Perret, Laurent Derré, et al.Journal for Immunotherapy of Cancer|September 27, 2018
Correction to: CART cells are prone to Fas- and DR5-mediated cell deathBenjamin O Tschumi, Nina Dumauthioz, Bastien Marti, et al.Pageof 3